

# **Liver Canada**

## **Financial Statements**

**For the Year Ended December 31, 2024**

## INDEPENDENT AUDITOR'S REPORT

To the Directors of Liver Canada

### *Qualified Opinion*

We have audited the financial statements of Liver Canada (the "Organization"), which comprise the statement of financial position as at December 31, 2024, and the statements of operations, changes in fund balances and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the possible effects of the matter described in the *Basis for Qualified Opinion* section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of the Organization as at December 31, 2024, and results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

### *Basis for Qualified Opinion*

In common with many not-for-profit organizations, the Organization derives chapter and other revenues directly from the public, the completeness of which is not susceptible to satisfactory audit verification. Accordingly, verification of these revenues was limited to the amounts recorded in the records of the Organization. Therefore, we were not able to determine whether any adjustments might be necessary to revenues, excess (deficiency) of revenues over expenses, and cash flows from operations for the years ended December 31, 2024 and 2023, current assets as at December 31, 2024 and 2023, and net assets as at January 1 and December 31 for both the 2024 and 2023 years. Our audit opinion on the financial statements for the year ended December 31, 2023 was modified accordingly because of the possible effects of this limitation of scope.

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Organization in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.


### *Responsibilities of Management and Those Charged with Governance for the Financial Statements*

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Organization's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Organization or to cease operations, or has no realistic alternative but to do so.

THE POWER OF BEING UNDERSTOOD  
ASSURANCE | TAX | CONSULTING

RSM Canada LLP is a limited liability partnership that provides public accounting services and is the Canadian member firm of RSM International, a global network of independent assurance, tax and consulting firms. Visit [rsmcanada.com/aboutus](https://rsmcanada.com/aboutus) for more information regarding RSM Canada LLP and RSM International.

A large, abstract, black and white graphic in the bottom right corner, resembling a stylized staircase or a series of overlapping rectangular blocks.

Those charged with governance are responsible for overseeing the Organization's financial reporting process.

*Auditor's Responsibilities for the Audit of the Financial Statements*

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Organization's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Organization's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Organization to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*RSM Canada LLP*

Chartered Professional Accountants  
Licensed Public Accountants  
May 2, 2025  
Toronto, Ontario

**Liver Canada**  
**Statement of Operations**  
**Year Ended December 31, 2024**

	General Fund		Research Trust Funds		Medical Research Fund		Total
	2024	2023	2024	2023	2024	2023	2024 2023
<b>Revenue</b>							
Contributions							
Unrestricted donations	\$ 1,490,768	\$ 1,820,693	\$ -	\$ -	\$ -	\$ -	\$ 1,490,768 \$ 1,820,693
Chapter revenues							
Unrestricted	1,130,932	1,076,209	-	-	-	-	1,130,932 1,076,209
Gaming	40,757	206,990	-	-	-	-	40,757 206,990
Externally restricted receipts	-	-	50,000	163,471	-	-	50,000 163,471
Contribution for research programs							
Externally restricted receipts	-	-	88,648	602,973	-	-	88,648 602,973
	<b>2,662,457</b>	<b>3,103,892</b>	<b>138,648</b>	<b>766,444</b>	<b>-</b>	<b>-</b>	<b>2,801,105 3,870,336</b>
<b>Expenses (Note 10)</b>							
Direct program costs							
Education	615,629	478,128	-	-	-	-	615,629 478,128
Public information	572,901	606,368	-	-	-	-	572,901 606,368
Chapter	124,019	111,516	-	-	-	-	124,019 111,516
Gaming	9,226	39,166	-	-	-	-	9,226 39,166
Research and project restricted disbursements							
(Research and Trust Funds - Schedule 1)							
Operating	-	-	869,887	4,009,536	135,000	127,982	1,004,887 4,137,518
Administration	1,325,890	1,431,522	-	-	-	-	1,325,890 1,431,522
Fundraising	787,515	761,910	-	-	-	-	787,515 761,910
	<b>3,435,180</b>	<b>3,428,610</b>	<b>869,887</b>	<b>4,009,536</b>	<b>135,000</b>	<b>127,982</b>	<b>4,440,067 7,566,128</b>
<b>Deficiency of revenues over expenses from operations</b>	<b>(772,723)</b>	<b>(324,718)</b>	<b>(731,239)</b>	<b>(3,243,092)</b>	<b>(135,000)</b>	<b>(127,982)</b>	<b>(3,695,792)</b>
Investment revenues (expenses)							
Unrealized gains (losses) on investments	(63,298)	71,375	(111,137)	125,325	(236)	12,002	(174,671) 208,702
Interest, dividends and realized gains on investments (Note 4)	350,507	296,844	593,190	558,540	1,160	41,830	944,857 897,214
	<b>287,209</b>	<b>368,219</b>	<b>482,053</b>	<b>683,865</b>	<b>924</b>	<b>53,832</b>	<b>770,186 1,105,916</b>
<b>Excess (deficiency) of revenues over expenses</b>	<b>\$ (485,514)</b>	<b>\$ 43,501</b>	<b>\$ (249,186)</b>	<b>\$ (2,559,227)</b>	<b>\$ (134,076)</b>	<b>\$ (74,150)</b>	<b>\$ (868,776) \$ (2,589,876)</b>

**Liver Canada**  
**Statement of Changes in Fund Balances**  
**Year Ended December 31, 2024**

	General Fund		Research Trust Funds		Medical Research Fund		Total	
	2024	2023	2024	2023	2024	2023	2024	2023
<b>Fund balance - beginning of year</b>	\$ 2,785,888	\$ 2,499,310	\$ 2,909,502	\$ 5,657,928	\$ 145,972	\$ 274,000	\$ 5,841,362	\$ 8,431,238
Excess (deficiency) of revenues over expenses	(485,514)	43,501	(249,186)	(2,559,227)	(134,076)	(74,150)	(868,776)	(2,589,876)
Interfund transfers (Note 5)	1,067	243,077	(143)	(189,199)	(924)	(53,878)	-	-
<b>Fund balance - end of year</b>	<b>\$ 2,301,441</b>	<b>\$ 2,785,888</b>	<b>\$ 2,660,173</b>	<b>\$ 2,909,502</b>	<b>\$ 10,972</b>	<b>\$ 145,972</b>	<b>\$ 4,972,586</b>	<b>\$ 5,841,362</b>

The following is a summary of the above funds as at December 31 classified as restricted, unrestricted and committed:

	2024	2023
Externally restricted research trust funds (Schedule 1)	\$ 2,660,173	\$ 2,909,502
Committed for medical research	10,972	145,972
General fund		
Geographically restricted (Note 3)	31,531	167,824
Invested in tangible capital assets (Note 6)	130,364	138,808
Unrestricted funds	2,139,546	2,479,256
	<b>\$ 4,972,586</b>	<b>\$ 5,841,362</b>

**Liver Canada**  
**Statement of Financial Position**  
**As at December 31, 2024**



	General Fund		Research Trust Funds		Medical Research Fund		Total
	2024	2023	2024	2023	2024	2023	2024 2023
<b>Assets</b>							
<b>Current</b>							
Cash and cash equivalents (Note 3)	\$ 1,023,976	\$ 1,054,198	\$ 421,825	\$ 501,377	\$ -	\$ 125,000	\$ 1,445,801 \$ 1,680,575
Accounts receivable	117,516	68,362	-	-	-	-	117,516 68,362
Prepaid expenses	43,803	28,332	-	-	-	-	43,803 28,332
	1,185,295	1,150,892	421,825	501,377	-	125,000	1,607,120 1,777,269
Investments (Note 4)	1,275,079	1,883,670	2,238,348	3,182,089	10,972	20,972	3,524,399 5,086,731
Tangible capital assets (Note 6)	130,364	138,808	-	-	-	-	130,364 138,808
	\$ 2,590,738	\$ 3,173,370	\$ 2,660,173	\$ 3,683,466	\$ 10,972	\$ 145,972	\$ 5,261,883 \$ 7,002,808

**Liabilities and Fund Balances**

<b>Current</b>							
Accounts payable and accrued liabilities	\$ 205,714	\$ 290,345	\$ -	\$ 773,964	\$ -	\$ -	\$ 205,714 \$ 1,064,309
Deferred lease inducement	11,295	11,295	-	-	-	-	11,295 11,295
	217,009	301,640	-	773,964	-	-	217,009 1,075,604
Deferred lease inducement	72,288	85,842	-	-	-	-	72,288 85,842
	289,297	387,482	-	773,964	-	-	289,297 1,161,446
Fund balances	2,301,441	2,785,888	2,660,173	2,909,502	10,972	145,972	4,972,586 5,841,362
	\$ 2,590,738	\$ 3,173,370	\$ 2,660,173	\$ 3,683,466	\$ 10,972	\$ 145,972	\$ 5,261,883 \$ 7,002,808

Commitments (Note 7)

APPROVED ON BEHALF OF THE BOARD OF DIRECTORS

 Director  
 Director

**Liver Canada**  
**Statement of Cash Flows**  
**Year Ended December 31, 2024**

	General Fund 2024	Research Trust Funds 2024	Medical Research Fund 2024	Total 2024	Total 2023
<b>Cash and cash equivalents provided by (used in)</b>					
<b>Operating</b>					
Deficiency of revenues over expenses	\$ (485,514)	\$ (249,186)	\$ (134,076)	\$ (868,776)	\$ (2,589,876)
Items not affecting cash:					
Interfund transfers	1,067	(143)	(924)	-	-
Amortization	25,249	-	-	25,249	23,972
Recognition of deferred lease inducement	(13,554)	-	-	(13,554)	(13,554)
Unrealized loss on investments	63,298	111,137	236	174,671	(208,702)
Realized gain on investments	(281,753)	(539,631)	(28,294)	(849,678)	(725,598)
<b>Change in non-cash operating assets and liabilities</b>					
Accounts receivable	(691,207)	(677,823)	(163,058)	(1,532,088)	(3,513,758)
Prepaid expenses	(49,154)	-	-	(49,154)	62,382
Accounts payable and accrued liabilities	(15,471)	-	-	(15,471)	(1,742)
Long-term liabilities	(84,631)	(773,964)	-	(858,595)	720,975
	-	-	-	-	(10,200)
	(840,463)	(1,451,787)	(163,058)	(2,455,308)	(2,742,343)
<b>Investing</b>					
Purchase of tangible capital assets	(16,805)	-	-	(16,805)	(21,478)
Purchase of investments	(136,304)	(261,056)	(13,686)	(411,046)	(810,200)
Proceeds from sale of investments	963,350	1,633,291	51,744	2,648,385	3,287,986
	810,241	1,372,235	38,058	2,220,534	2,456,308
<b>Decrease in cash and cash equivalents during the year</b>	(30,222)	(79,552)	(125,000)	(234,774)	(286,035)
<b>Cash and cash equivalents, beginning of year</b>	1,054,198	501,377	125,000	1,680,575	1,966,610
<b>Cash and cash equivalents, end of year</b>	\$ 1,023,976	\$ 421,825	\$ -	\$ 1,445,801	\$ 1,680,575

## 1. NATURE OF OPERATIONS

Liver Canada (the "Organization" or "LC") was formed in 1969 as the Canadian Liver Foundation ("CLF") under the laws of the Province of Ontario. In 1989, the Organization was dissolved and its assets were transferred to another foundation with the same name incorporated under the Canada Corporations Act as a not-for-profit organization without share capital. The Organization continued under the Canada Not-for-Profit Corporations Act in 2014. The name was formally changed to Liver Canada in 2024.

LC is the national leader in liver health, transforming knowledge into action through groundbreaking research, public education, and dedicated patient support. LC is the leading non-profit organization in Canada focused on liver health. It is a key funding source for patient support and services, advocacy, public awareness, community engagement and research into liver diseases.

The Organization is registered as a charity under Section 149 (1)(f) of the Income Tax Act (Canada) and, as such is exempt from income taxes.

## 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

### Basis of Presentation

These financial statements were prepared in accordance with Canadian accounting standards for not-for-profit organizations and reflect the combined activity and financial position of the Organization's National Offices and its volunteer Chapters across Canada. The significant accounting policies followed in the preparation of the financial statements are summarized below.

### Fund Accounting

The activities of the Organization are accounted for utilizing the concepts of restricted fund accounting. Accordingly, three funds - General Fund, Research Trust Funds, and an internally restricted Medical Research Fund have been established to account for the activities described below:

The **General Fund** reflects the health promotion, patient support, public information, fundraising and administration activities of the Organization. Accordingly, all revenue received and expenditures incurred for these purposes, together with all unrestricted donations received are recorded in this fund.

The **Research Trust Funds** comprise the following 25 externally restricted funds:

The **W.P. Gillbride Research Trust Fund** was created in 1981 in memory of a past president through donations made to the Organization, specifically to sponsor the W.P. Gillbride Visiting Scientists program.



## 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

### Fund Accounting (Cont'd)

The **Research Trust Funds** comprise the following 25 externally restricted funds: (Cont'd)

The **CanHepC** (formally known as Hepatitis C Program) was established in 2000 through Health Canada to enhance existing programs, as well as provide new programs and services to people living with hepatitis C. In addition, the Organization received funding to develop and distribute hepatitis C medical information to 35,000 Canadian physicians by mail. In 2002, the NCRTP-Hep C Trust Fund was established to support a national, multicentre, trans-disciplinary program created to enhance research, training and knowledge translation in the area of hepatitis C. In July 2015, the NCRTP-HepC program expanded the research program further and re-established itself as the Canadian Network of Hepatitis C (CanHepC). The main objective of the CanHep C is to establish a continuous pipeline from the discovery stage to implementation stage to reduce hepatitis C transmission, cure and improve the quality of life of people with hepatitis C, and to work towards the elimination of the hepatitis C infection in Canada.

The **MUHC Trust Fund** was established in 2008 as a collaborative partnership agreement to support research and education and the McGill University Health Centre in Montreal, Quebec.

The **HepB Study Group-CLF Trust Fund** was established in 2017 as a cooperative partnership agreement between LC and Principle Investigators, Drs. Peter Kwan and Francis Ho, to support the "H Be Proactive" study on hepatitis B prevalence in the Greater Vancouver Area.

The **CLF-CDTRP Trust Fund** (previously known as the CLF-CNTRP Trust Fund) was established in 2012 as a cooperative partnership agreement with the Canadian National Transplant Research Program (CNTRP) to enhance the survival and quality of life of Canadians needing transplantation, through multi-disciplinary, collaborative and leading edge research. In 2019, the Canadian National Transplant Research Program (CNTRP) changed its program name to the Canadian Donation and Transplantation Research Program (CDTRP).

The **CLF-UCalgary Trust Fund** was established in 2019 as a cooperative partnership agreement between LC and the Governors of the University of Calgary to support mutually agreeable liver research and education activities which will improve clinical care, increase research productivity and enhance education in liver disease in Southern Alberta.

The remaining 19 Trust Funds are listed in Schedule 1 of the financial statements.

The **Medical Research Fund** was established in 1990 to account for medical research projects established by the Board of Directors and supported primarily by the unrestricted funds of the Organization. Donations received to fund specific medical research projects are also reflected in this fund.

### Revenue and Expenditure Recognition

The accrual basis of accounting is used for reporting revenues and expenditures, except for unrestricted donations and bequests, which are accounted for on a cash basis unless the amount can be reasonably estimated and ultimate collection is reasonably assured. The Organization recognizes government assistance towards current expenses in the statement of operations. When government assistance relates to future expenses, amounts are deferred and recognized as the expenses are incurred.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**Funds for Designated Projects**

Funds for Research and Education projects that are restricted by the funders for specific purposes are recorded as receipts directly in either the appropriate Research Trust Funds or Medical Research Fund as designated under the terms of the relevant agreement.

Research projects are typically funded over a two to three year period. The receipts that are restricted for application to these projects are recorded on receipt of the funding.

Research grant disbursements are expensed as incurred in accordance with the term of the respective funding agreements.

**Donated Services and Materials**

These financial statements do not reflect the value of services received during the year due to difficulties in determining the fair value.

**Tangible Capital Assets and Amortization**

Tangible capital assets are recorded at cost less accumulated amortization and amortized over their estimated useful lives at the following rates and methods:

Furniture, fixtures and equipment	20%	declining balance method
Leasehold improvements	Term of the lease	straight-line method

When conditions indicate a tangible capital asset is impaired, the carrying value of the tangible capital asset is written down to the asset's fair value or replacement cost. The write down of the tangible capital asset is recorded as an expense in the statement of operations under the general fund. A write-down shall not be reversed.

**Software Services**

During the year, the Organization adopted Accounting Guidelines AcG-20, "Customer's Accounting for Cloud Computing Arrangements" which is effective for fiscal years beginning on or after January 1, 2024. The guideline was adopted retrospectively. There was no impact on the adoption of this guideline as there were no changes in the recording of software service fees and other expenses related to cloud computing arrangements on adoption. The Organization applied the simplification method and software service fees and other expenses related to cloud computing arrangements are expensed as incurred in Statement of Operations. Expenses are recorded and allocated as disclosed in note 10 of the financial statements.

**Deferred Lease Inducement**

Deferred lease inducements are amortized over the term of the lease.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**Use of Estimates**

The preparation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations requires management to make estimates and assumptions that affect the reported amount of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. These estimates are based on management's best efforts and knowledge of current events and actions the Organization may undertake. Significant estimates in these financial statements include the allocation of general expenses (Note 10).

**Allocation of Expenses**

The Organization engages in research and education programs. The costs of each program include costs directly related to providing the program, as well as an allocation of a number of general support expenses relating to personnel, premises and computer outsourcing that are common to the administration of the Organization. Salaries and benefits are allocated to programs based on staff estimates of time spent on each functional area. Office rent and computer outsourcing costs are allocated between departments based on headcount and functional area. Fundraising costs are not allocated.

**Financial Instruments**

*Measurement*

Financial instruments are financial assets or financial liabilities of the Organization where, in general, the Organization has the right to receive cash or another financial asset from another party or the Organization has the obligation to pay another party cash or other financial assets.

The Organization initially measures its financial assets and financial liabilities at fair value.

The Organization subsequently measures its financial assets and financial liabilities, which are not measured at fair value at each statement of financial position date, at amortized cost.

Financial assets measured at amortized cost include cash and cash equivalents and accounts receivable.

Financial liabilities measured at amortized cost include accounts payable and accrued liabilities.

The Organization's financial assets measured at fair value at each statement of financial position date include a portfolio of equity investments with quoted shares/units in an active market and pooled funds measured based on year-end quoted market prices of the underlying assets in the pooled funds.

The Organization accounts for regular purchases and sales of financial assets using trade date accounting.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Cont'd)**

**Financial Instruments (Cont'd)**

*Transactions costs*

Transaction costs and financing fees are expensed as incurred for financial instruments measured at fair value and capitalized for financial instruments that are subsequently measured at cost or amortized cost.

The Organization recognizes its transaction costs in net income in the period incurred for its equity investments and all other financial assets and liabilities subsequently measured at fair value. Financial instruments, that are subsequently measured at cost or amortized cost, are adjusted by the transaction costs and financing fees that are directly attributable to their origination, issuance or assumption.

*Impairment*

Financial assets measured at cost or amortized cost are tested for impairment, at the end of each year, to determine whether there are indicators that the asset may be impaired. The amount of the write-down, if any, is recognized in excess (deficiency) of revenues over expenses. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account. The reversal may be recorded provided it is no greater than the amount that had been previously reported as a reduction in the asset and it does not exceed original cost. The amount of the reversal is recognized in operations.

**3. RESTRICTED CASH**

Included in cash and cash equivalents are restricted amounts as follows:

(a) Gaming revenues

\$31,531 (2023 - \$167,824) earned in gaming revenues, and which is restricted by local authorities for use in the province where the gaming revenues were earned.

(b) Investments held in cash and cash equivalents

\$12,157 (2023 - \$21,934) being held in the Organization's investment account in accordance with the Investment Policy Statement (IPS) approved by the Organization's Board of Directors. This amount is intended for deployment in investing activities under the Organization's IPS and as such is not generally available for use towards operating expenses.

**Liver Canada**  
**Notes to Financial Statements**  
**December 31, 2024**

**4. INVESTMENTS**

	2024	2023
Cash and cash equivalents	\$ 12,157	\$ 21,934
Bonds	1,251,341	1,664,562
Equities	2,273,058	3,422,169
	3,536,556	5,108,665
Less: cash and cash equivalents (Note 3)	(12,157)	(21,934)
	<b>\$ 3,524,399</b>	<b>\$ 5,086,731</b>

Investments are stated at fair value at year-end and have an original cost of \$2,405,357 (2023 - \$3,801,350).

Included in interest, dividends and realized capital gains (losses) are realized capital gains of \$849,678 (2023 - realized capital gain of \$725,599).

**5. INTERFUND TRANSFERS**

The interfund balances represent the accumulated transfers amongst the Organization's specific fund balances.

**6. TANGIBLE CAPITAL ASSETS**

	Cost	Accumulated Amortization	Net 2024	Net 2023
Furniture, fixtures and equipment	\$ 488,083	\$ 441,302	\$ 46,781	\$ 41,672
Leasehold improvements	305,441	221,858	83,583	97,136
	<b>\$ 793,524</b>	<b>\$ 663,160</b>	<b>\$ 130,364</b>	<b>\$ 138,808</b>

**7. COMMITMENTS**

At December 31, 2024, minimum aggregate lease payments under operating leases for rental of premises and equipment, and donor related computer software ("CRM"), over the next five fiscal years approximate the following:

2025	\$ 461,179
2026	285,920
2027	249,570
2028	207,638
2029	195,650
Thereafter	228,698
	<b>\$ 1,628,655</b>

**Liver Canada**  
**Notes to Financial Statements**  
**December 31, 2024**

---

**7. COMMITMENTS (Cont'd)**

The above commitments schedule includes the National Office lease which matures in 2031, and the CRM contract costs related to maintenance fees.

Rental of premises and equipment	\$ 1,373,233
CRM maintenance	115,055
Other	140,367
	<hr/>
	<b>\$ 1,628,655</b>

**8. ALBERTA GOVERNMENT AND PROGRAM SUPPORT SERVICES INFORMATION**

The total amount paid as remuneration to employees of the Organization whose principal duties involve fundraising was \$427,945 (2023 - \$428,357). The amounts paid as remuneration to a fundraising business, including expenses or fees paid by the Organization on behalf of the fundraising business or as reimbursements to the fundraising business was \$25,830 (2023 - \$5,789).

**9. LETTER OF CREDIT**

The Organization has access to a revolving demand credit facility bearing interest at Royal Bank of Canada prime rate plus 3.00% per annum (5.45% prime rate at December 31, 2024) to a maximum of \$100,000. The facility is secured by a general security agreement over all property. The balance outstanding under this facility was \$Nil (2023 - \$Nil) at year end.

**10. GENERAL FUND EXPENSE ALLOCATION**

	Chapter	Gaming	Education	Public Information	Fundraising	Administration	Total
Direct costs	\$ 52,349	\$ 9,226	\$ 312,299	\$ 296,314	\$ 398,783	\$ 325,384	\$ 1,394,355
Allocated costs:							
Salaries and benefits	71,670	-	218,274	215,233	345,223	838,171	1,688,571
Office rent	-	-	47,650	28,875	14,438	77,001	167,964
Computer outsourcing	-	-	37,406	32,479	29,071	85,334	184,290
	<hr/>						
<b>2024 Total</b>	<b>\$ 124,019</b>	<b>\$ 9,226</b>	<b>\$ 615,629</b>	<b>\$ 572,901</b>	<b>\$ 787,515</b>	<b>\$ 1,325,890</b>	<b>\$ 3,435,180</b>

**10. GENERAL FUND EXPENSE ALLOCATION (Cont'd)**

	Chapter	Gaming	Education	Public Information	Fundraising	Administration	Total
Direct costs	\$ 49,579	\$ 39,166	\$ 76,310	\$ 360,553	\$ 376,190	\$ 364,439	\$ 1,266,237
Allocated costs:							
Salaries and benefits	61,937	-	282,832	184,431	344,622	907,663	1,781,485
Office rent	-	-	57,061	28,531	14,265	77,460	177,317
Computer outsourcing	-	-	61,925	32,853	26,833	81,960	203,571
2023 Total	\$ 111,516	\$ 39,166	\$ 478,128	\$ 606,368	\$ 761,910	\$ 1,431,522	\$ 3,428,610

**11. FINANCIAL RISK MANAGEMENT**

The Organization is exposed to various risks through its financial instruments and has a comprehensive risk management framework to monitor, evaluate and manage these risks. There has been no change to the Organization's risk exposure from prior year. The following analysis provides information about the Organization's risk exposure and concentration as of December 31, 2024.

**Credit Risk**

Credit risk arises from the potential non-performance by counterparties of contract obligations which could lead to a financial loss to the Organization. The Organization's credit risk relates to its accounts receivable. In the opinion of management, the credit risk exposure to the Organization is not significant due to the nature of its accounts receivable.

**Liquidity Risk**

Liquidity risk is the risk that the Organization will encounter difficulty in meeting its obligations. The Organization meets its liquidity requirements by preparing and monitoring detailed forecasts of cash flows from operations, anticipating investing and financing activities and holding assets that can be readily converted to cash.

**Market Risk**

Market risk is the risk that the fair value or expected future cash flows of a financial instrument will fluctuate because of changes in market prices. Market risk comprises three types of risk: currency rate risk, interest rate risk and other price risk.

**11. RISK MANAGEMENT (Cont'd)**

**Currency Risk**

Currency risk is the risk that the fair value of or future cash flows from a financial instrument denominated in currencies other than the functional currency of the Organization will fluctuate due to changes in foreign exchange rates. The Organization is exposed to currency risk as it invests in foreign bonds and equities totaling USD \$1,320,390 (2023 - USD \$1,667,605), which are converted to the Organization's functional currency (CAD) in determining fair value. Accordingly, any change in fair value includes an element of foreign currency translation gain/loss as well as underlying change in market values for the foreign currency investments.

**Interest Rate Risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Organization is exposed to interest rate risk arising on its fixed income instruments, as disclosed in Note 4.

**Other Price Risk**

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Organization is exposed to other price risk through its investments in quoted shares as disclosed in Note 4.



# Liver Canada

## Research and Trust Funds - Schedule 1

Year Ended December 31, 2024

	Balance, beginning of the year	Fund Transfers	Contributions	Chapter donations	Investment gain (loss)	Program costs	Balance, end of year
W.P. Gilbride	\$ 170,328	\$ -	\$ -	\$ -	\$ 44,008	\$ -	\$ 214,336
CanHepC	1,211,655	-	-	-	259,149	(255,465)	1,271,139
MUHC	141,319	-	55,800	-	36,826	-	178,145
HepB Study Group	392,241	-	-	50,000	38,214	(200,218)	280,237
CLF - CDTRP	299,563	-	2,336	-	65,221	(2,026)	365,094
CLF - UCalgary	115,083	-	-	-	11,189	-	126,272
Other	579,313	(143)	30,512	-	27,446	(412,178)	224,950
	\$ 2,909,502	\$ (143)	\$ 88,648	\$ 50,000	\$ 482,053	\$ (869,887)	\$ 2,660,173

The following funds comprise the line 'Other':

- The Sarah Ralston Endowment Fund
- The Chair of Hepatology Trust Fund
- The Raj Bhargava Endowment Fund
- The CPHRG Trust Fund
- The CASL Trust Fund
- The CLF-Dalhousie Digestive Care & Endoscopy Trust Fund
- The Canadian Liver Research Group Trust Fund
- The CLF-Lee Liver Research Trust Fund
- The Sexton Liver Cancer Research Trust Fund
- The CLF-RECAP Trust Fund
- The CLTN-CLF Trust Fund
- The CLF-Krahn Liver Research Trust Fund
- The CCC-CLF Trust Fund
- The CaNAL-CLF Trust Fund
- The CLF-Canadian Liver Meeting Trust Fund
- The CLF-SIDCN Trust Fund
- The CLF-HCV2021 Trust Fund
- The CLF-CanNASH Trust Fund
- The CLF-OSN Trust Fund

See accompanying notes